⌘K
t
On 01 November 2024, Haleon plc announced an update on its Total Voting Rights and Capital. As at 31 October 2024, the company had 9,083,725,919 ordinary shares of £0.01 each issued, of which 30,365,037 were held as treasury shares. This resulted in 9,053,360,882 ordinary shares with voting rights.
| Date | 1 Nov 2024 |
| Time | 11:45:00 |
| Category | Capital structure |
| ID | 6555K |
Haleon plc: Total Voting Rights and Capital
1 November 2024: As at 31 October 2024 the total number of shares issued by Haleon plc ("Haleon" or the "Company") is 9,083,725,919 ordinary shares of £0.01 each, of which 30,365,037 are held as treasury shares.
Therefore, the number of ordinary shares with voting rights is 9,053,360,882 and this figure should be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Notifiable interests in Haleon should be sent to: [email protected]
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com.